We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: metastatic hormone-sensitive prostate cancer
MedXY News
EnglishTag

metastatic hormone-sensitive prostate cancer

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Metformin in Metastatic Hormone-Sensitive Prostate Cancer Undergoing Androgen Deprivation Therapy: Insights from the STAMPEDE Phase 3 Trial and Contemporary Evidence
Clinical Updatesandrogen deprivation therapymetastatic hormone-sensitive prostate cancer

Metformin in Metastatic Hormone-Sensitive Prostate Cancer Undergoing Androgen Deprivation Therapy: Insights from the STAMPEDE Phase 3 Trial and Contemporary Evidence

By MedXY|Nov 17, 2025

Comprehensive review of metformin’s role in metastatic prostate cancer with ADT highlights STAMPEDE trial’s findings: no significant overall survival benefit but metabolic side-effect mitigation. Integration of other RCTs outlin

Optimizing Therapy for Older Patients with Metastatic Hormone-Sensitive Prostate Cancer: Insights from a Network Meta-Analysis of Doublet versus Triplet Regimens
newsdarolutamide
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
metastatic hormone-sensitive prostate cancer

Optimizing Therapy for Older Patients with Metastatic Hormone-Sensitive Prostate Cancer: Insights from a Network Meta-Analysis of Doublet versus Triplet Regimens

By MedXY|Oct 30, 2025

This network meta-analysis reveals that triplet therapy with darolutamide, ADT, and docetaxel offers the greatest overall survival benefit for older patients with metastatic hormone-sensitive prostate cancer, highlighting the need to balanc

Age-Related Impact of Treatment Intensification on Survival in Metastatic Hormone-Sensitive Prostate Cancer
newsageandrogen receptor pathway inhibitors

Age-Related Impact of Treatment Intensification on Survival in Metastatic Hormone-Sensitive Prostate Cancer

By MedXY|Oct 30, 2025

Systemic treatment intensification improves overall survival in metastatic hormone-sensitive prostate cancer, but its benefit varies by age and disease volume. Older men, particularly with low-volume disease, may have limited survival gains

Impact of Enzalutamide on PSA Dynamics and Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: Insights from the ARCHES Trial Secondary Analysis
Oncologyandrogen deprivation therapyEnzalutamide

Impact of Enzalutamide on PSA Dynamics and Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: Insights from the ARCHES Trial Secondary Analysis

By MedXY|Oct 21, 2025

This secondary analysis of the ARCHES trial demonstrates that enzalutamide plus ADT improves progression-free and overall survival in mHSPC patients across PSA levels, with undetectable PSA strongly predicting favorable outcomes.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities